WHO warns of “tsunami of cases” from Omicron, Delta

Geneva, The World Health Organization (WHO) has cautioned that the more transmissible Omicron together with the currently circulating Delta variants might lead to “a tsunami of cases,” putting immense pressure on national health systems.

Recapping WHO’s response since the onset of the Covid-19 pandemic, WHO Director General Tedros Adhanom Ghebreyesus on Wednesday said at a press briefing that he’s “highly concerned that Omicron being more transmissible, circulating at the same time as Delta — is leading to a tsunami of cases.”

“This is and will continue to put immense pressure on exhausted health workers and health systems on the brink of collapse and again disrupting lives and livelihoods,” he added, citing the pressure as not only new Covid-19 patients requiring hospitalisation but also a large number of health workers getting sick themselves.

Tedros reiterated his concern over a recent narrative that Omicron has been causing milder or less severe diseases, Xinhua news agency reported.

“But we are undermining the other side at the same time — it could be dangerous… we shouldn’t undermine the bad news just focusing on the good news,” he said.

“We don’t want people to be complacent, saying this is not severe, this is mild. And we have to be very careful in that narrative,” he added.

According to Mike Ryan, Executive Director of the WHO’s Health Emergencies Program, though Omicron looks like being more transmissible, having a shorter incubation period, and causing a mild disease, it’s based on the largely young population that the variant has been infecting.

Since the Omicron wave has not been fully established in the broader population, Ryan said he’s “a little nervous to make positive predictions until we see how well the vaccine protection is going to work in the older and more vulnerable populations.”

“I think it’s really important over the coming weeks that we keep suppressing transmission of both variants to the minimum that we can,” he added.

–IANs

  • Related Posts

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per ml. The…

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    New Delhi: Serious legal gaps in the Drugs and Cosmetics Act, 1940, combined with acute shortages of manpower and infrastructure, continue to impede the Central Drugs Standard Control Organisation (CDSCO)…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

    FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development